Edition:
India

BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

6.25USD
2:29am IST
Change (% chg)

$-0.19 (-2.95%)
Prev Close
$6.44
Open
$6.50
Day's High
$7.25
Day's Low
$6.05
Volume
120,359
Avg. Vol
18,075
52-wk High
$12.00
52-wk Low
$2.41

Latest Key Developments (Source: Significant Developments)

Bioxcel Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 26 Sep 2019 

Sept 25 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BIOXCEL THERAPEUTICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $19.0 MILLION OF SHARES OF ITS COMMON STOCK.BIOXCEL THERAPEUTICS INC - ALL OF COMMON STOCK IS BEING OFFERED BY BTI.  Full Article

Bioxcel Therapeutics Announces Bxcl501 Met Primary Endpoint In Phase 1B Placebo-Controlled Trial For Agitation In Patients With Schizophrenia
Monday, 22 Jul 2019 

July 22 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES BXCL501 MET PRIMARY ENDPOINT IN PHASE 1B PLACEBO-CONTROLLED TRIAL IN THE TREATMENT OF AGITATION IN PATIENTS WITH SCHIZOPHRENIA.BIOXCEL THERAPEUTICS INC - WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS ACROSS ENTIRE DOSE RANGE.BIOXCEL THERAPEUTICS INC - BELIEVES RESULTS SUGGEST A PREDICTABLE AND DOSE-DEPENDENT RESPONSE FOR BXCL501.BIOXCEL THERAPEUTICS INC - BXCL501 WAS WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS ACROSS ENTIRE DOSE RANGE.BIOXCEL THERAPEUTICS INC - PLANS TO MEET WITH FDA TO OBTAIN ADDITIONAL FEEDBACK ON PROGRESSING TO A PHASE 3 PIVOTAL TRIAL.  Full Article

Bioxcel Therapeutics Completes Dosing Two Cohorts Of Agitated Schizophrenia Patients With Bxcl501 In A Phase 2 Efficacy Trial
Monday, 10 Jun 2019 

June 10 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS COMPLETES DOSING TWO COHORTS OF AGITATED SCHIZOPHRENIA PATIENTS WITH BXCL501 IN A PHASE 2 EFFICACY TRIAL.BIOXCEL THERAPEUTICS INC - ON TRACK TO ANNOUNCE TOP LINE RESULTS FROM PHASE 2 EFFICACY TRIAL IN 3Q 2019.BIOXCEL THERAPEUTICS INC - PLANNING TO INITIATE FIRST PHASE 3 PIVOTAL TRIAL IN 4Q 2019.  Full Article

BioXcel Therapeutics Files For Mixed Shelf Of Upto $200 Million
Tuesday, 2 Apr 2019 

April 1 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Bioxcel Therapeutics Receives FDA Fast Track Designation For Bxcl501 For Acute Treatment Of Agitation
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR BXCL501 FOR ACUTE TREATMENT OF AGITATION.BIOXCEL THERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE DATA FROM BXCL501 STUDY IN FIRST HALF OF 2019.  Full Article

Bioxcel Therapeutics Doses First Subjects In Safety Study Of BXCL501 For Acute Treatment Of Agitation
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS DOSES FIRST SUBJECTS IN PHARMACOKINETIC (BIOAVAILABILITY) AND SAFETY STUDY OF BXCL501 FOR ACUTE TREATMENT OF AGITATION.BIOXCEL THERAPEUTICS INC -RESULTS EXPECTED TO SUPPORT DOSE SELECTION FOR ANTICIPATED REGISTRATION TRIALS IN 2019.BIOXCEL THERAPEUTICS -EXPECTS TO REPORT TOP-LINE DATA FROM STUDY IN H1 2019.  Full Article

Bioxcel Therapeutics Announces FDA Acceptance Of IND For Lead Neuroscience Candidate, BXCL501 For Acute Treatment Of Agitation
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR LEAD NEUROSCIENCE CANDIDATE, BXCL501 FOR THE ACUTE TREATMENT OF AGITATION.BIOXCEL THERAPEUTICS INC SAYS PATIENT RECRUITMENT INITIATED AND DATA READ-OUT EXPECTED IN 1H 19.BIOXCEL THERAPEUTICS INC SAYS RESULTS TO SUPPORT DOSE SELECTION FOR REGISTRATION TRIAL EXPECTED TO INITIATE IN 2019.BIOXCEL THERAPEUTICS INC SAYS WITH FDA ACCEPTANCE OF IND, CO IS ON-TRACK TO DOSE SUBJECTS BY YEAR-END, WITH DATA EXPECTED IN FIRST HALF OF 2019.  Full Article

Bioxcel Therapeutics Qtrly Loss Per Share $0.31
Friday, 9 Nov 2018 

Nov 9 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS THIRD QUARTER 2018 QUARTERLY RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.31.BIOXCEL THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS TOTALED $47.1 MILLION..BIOXCEL THERAPEUTICS INC - EXPECT THAT DATA FROM IV DEX STUDIES IN PATIENTS WITH SCHIZOPHRENIA AND SDAT WILL BE AVAILABLE BY END OF 2018.  Full Article

Bioxcel Therapeutics Expands Immuno-Oncology Partnership With Nektar
Monday, 24 Sep 2018 

Sept 24 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS EXPANDS IMMUNO-ONCOLOGY PARTNERSHIP WITH NEKTAR INTO CLINICAL DEVELOPMENT IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - CO AND NEKTAR ARE EXPANDING THEIR ONGOING RESEARCH COLLABORATION INTO A NEW CLINICAL PARTNERSHIP.BIOXCEL THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, CO WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.  Full Article

Bioxcel Therapeutics Reports Q2 Net Loss Per Share $0.1
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.CLINICAL PROGRAMS IN NEUROSCIENCE (BXCL501) AND IMMUNO-ONCOLOGY (BXCL701) ON TRACK.QTRLY NET LOSS PER SHARE $0.1.  Full Article